Cytokinetics

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytokinetics focuses on aficamten development post-FDA action, eyes international growth

Cytokinetics is navigating challenges post-CRL for omecamtiv mecarbil while focusing on aficamten's development.
Financially, the company is balancing increased expenses with revenue growth and strategic investments in R&D.
Key milestones for 2023 include FDA meetings for omecamtiv mecarbil and data expectations for aficamten.
The company's emphasis on aficamten's differentiation and clinical progress signals a strategic shift in focus.

Cytokinetics shifts focus to cardiovascular pipeline, optimistic outlook ahead

Cytokinetics focusing on cardiovascular pipeline progress, redirecting resources.
Optimistic outlook for aficamten and other cardiovascular drug candidates.
Financially stable with cash reserves and strategic cost-saving measures.

Cytokinetics reports strong Q2 progress, eyes market expansion opportunities

Cytokinetics made significant strides in Q2 2023, advancing key studies and reducing operating spending to enhance financial stability.
Positive data and progress in cardiovascular therapies showcase the company's potential in treating HCM and positioning in the market.
While facing challenges in stock performance and data disclosures, Cytokinetics remains poised for growth with opportunities in novel therapies and market expansion.

Cytokinetics excels in Q3 with aficamten progress and commercial readiness

Cytokinetics demonstrated strong operational and financial performance in Q3 2023, with a focus on advancing the aficamten program and preparing for potential commercialization.
While facing challenges related to data interpretation complexities and real-world beta blocker usage, the company remains well-positioned with compelling clinical aspects of aficamten.
Opportunities lie in potential partnerships for capital access, broad market potential across regions, and upcoming data disclosures driving market differentiation.

Cytokinetics excels with positive aficamten trial results and strategic focus

Cytokinetics' Q4 2023 marked a significant milestone with positive aficamten trial results, strong financial standing, and strategic focus on regulatory advancements and market expansion.
The company's strengths lie in aficamten's efficacy, financial stability, and potential for differentiated labeling, while challenges include adoption transitions and data analysis complexities.
Opportunities abound in accelerating NDA submission, expanding patient reach, engaging with payors, and leveraging data insights for enhanced patient outcomes and market positioning.
Overall, Cytokinetics is poised for growth and impact in 2024, with a clear roadmap for success in advancing aficamten and maximizing its therapeutic potential in the HCM market.

Cytokinetics advances aficamten for HCM treatment amid financial strength

Cytokinetics is making significant strides in advancing aficamten for HCM treatment, supported by positive results and regulatory engagements.
The company's financial strength and strategic focus on commercial readiness position it well for future growth and market penetration.
Challenges lie in addressing unmet needs in pediatric HCM, enrollment completion for ongoing trials, and establishing treatment credibility.
Opportunities exist in expanding diagnosis potential, developing competitive treatment options, and enhancing regulatory alignment for global market access.

Cytokinetics advances obstructive HCM treatment with strong financials and strategic focus

Cytokinetics is poised for growth with FDA submission for aficamten and strong financial position.
Strategic focus on commercial preparations and clinical trials signals a commitment to future success.
Challenges in market competition and education require targeted efforts for successful product launch.
Emphasis on patient-centric approach and category expansion positions the company for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Food and Drug Administration is fast-tracking the biotech's lead drug candidate.

Here's Why Cytokinetics Is Skyrocketing 24.5% Today

Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options

FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure

Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q1 2020 Results - Earnings Call Transcript

Shares of a San Francisco-based biotech are up 40% year to date, but analysts think the stock is trading at only about half its 12-month estimated high of $30 and rate it a buy, according to CNN Money.

Cytokinetics Trading at Half High Target of $30

Top-line Results for GALACTIC-HF Expected in Q4 2020; Enrollment in METEORIC-HF Temporarily Suspended Top-line Results for GALACTIC-HF Expected in Q4 2020; Enrollment in METEORIC-HF Temporarily Suspended

Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic

Top-line Results for GALACTIC-HF Expected in Q4 2020 Top-line Results for GALACTIC-HF Expected in Q4 2020

Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

Cytokinetics: Multiple Growth Catalysts Ahead In 2020

SOUTH SAN FRANCISCO, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS). Previously reldesemtiv was granted orphan drug designation for the treatment of ALS by the U.S. Food & Drug Administration. Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA), as a potential treatment for people with ALS, SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q4 2019 Results - Earnings Call Transcript

In Vitro Studies Demonstrate Cardiac Troponin Activator Selectively Activates Cardiac Muscle Fibers with Little Effect on Slow Skeletal Muscle or Fast Skeletal Muscle

Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure

Amgen

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Community Health Systems

Endo International

Momenta Pharmaceuticals

Owens & Minor

The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.

Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks

Second Interim Analysis in GALACTIC-HF Expected to Occur in Q1 2020

Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach

Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants

Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.

Implied Volatility Surging for Cytokinetics (CYTK) Stock Options

Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway

Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones

Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule

Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274

SOUTH SAN FRANCISCO, Calif., Dec.  18, 2019  (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS). Previously reldesemtiv was granted orphan drug designation for the treatment of spinal muscular atrophy (SMA) by the FDA and by the European Medicines Agency. In collaboration with Astellas, Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA), as a potential treatment for people with ALS, SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

Subgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv with and without Concomitant Radicava® (edaravone) or Rilutek® (riluzole) Subgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv with and without Concomitant Radicava® (edaravone) or Rilutek® (riluzole)

Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND

Aerie Pharmaceuticals

Akebia Therapeutics

Novavax

Telesis Bio Inc

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

5 “Strong Buy” Biotech Stocks With More Than 80% Upside

SOUTH SAN FRANCISCO, Calif., Nov.  11, 2019  (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented in an Abstract Rapid Fire Oral presentation at the American Heart Association Scientific Sessions 2019 in Philadelphia on November 18, 2019. 

Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019

SOUTH SAN FRANCISCO, Calif., Nov.  08, 2019  (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has agreed to sell an aggregate of $120.0 million principal amount of its 4.00% convertible senior notes due 2026, or the notes, in an underwritten public offering. Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional $18.0 million aggregate principal amount of the notes in connection with the offering, solely to cover over-allotments. The aggregate principal amount of the offering was increased from the previously announced offering size of $100.0 million. The offering is expected to close on November 13, 2019, subject to customary closing conditions.

Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes

News of a public debt offering didn't go over well with investors.

News for Cytokinetics Stock (CYTK)